MYC and breast cancer: The results of the study showed that PRMT5 is overexpressed in breast cancer cell lines of varying aggressiveness, and that it promotes their growth by activating WNT/β‐CATENIN proliferative signalling through epigenetic silencing of pathway antagonists, DKK1 and DKK3, leading to enhanced expression of c‐MYC, CYCLIN D1 and SURVIVIN. Through chromatin immunoprecipitation (ChIP) studies, it was confirmed that PRMT5 binds to the promoter region of WNT antagonists, DKK1 and DKK3, and induces symmetric methylation of H3R8 and H4R3 histones.